BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanced Stent Technologies, Inc. Receives FDA Conditional Approval To Use PETAL(TM) Stent System In BOSS Trial And Enrolls First PETAL(TM) Stent System Patient


10/19/2005 5:10:19 PM

PLEASANTON, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Advanced Stent Technologies (AST), Inc., received FDA conditional approval to incorporate its bare metal novel PETAL(TM) coronary bifurcation stent and delivery system into its ongoing U.S. BOSS clinical trial on August 13, 2004 and has enrolled the first patient by Dean J. Kereiakes, M.D. at the Lindner Clinical Trial Center in Cincinnati, Ohio.

AST will immediately initiate three other clinical centers to utilize the PETAL(TM) stent system. The centers are Elyria Memorial Hospital, Elyria, OH, Scripps Memorial Hospital, La Jolla, CA, and Stanford University Medical Center, Stanford, CA.

The conditional approval specifies enrollment of up to 30 nonrandomized patients using the PETAL(TM) stent system. AST is currently responding to FDA questions to gain full approval for enrollment of up to 100 PETAL(TM) patients. AST anticipates adding an additional four to six centers in the next several months.

The company has previously enrolled patients into the BOSS trial using SLK-View(R) stent system, which features a side branch aperture lacking ostial elements and is the predecessor to the PETAL(TM) stent system. The PETAL(TM) stent system incorporates innovative "petal" strut elements that deploy approximately two millimeters into the side branch vessel, physically supporting and covering the carina and side branch ostium in a circumferential manner, while at the same time providing continuous and unimpeded access to the side branch through the side aperture created by the deployment of the "petal" strut elements. Many key interventional thought leaders believe the combination of stent ostial coverage with unrestricted access to the side branch will lead to improved acute and long-term outcomes for this complex lesion subset. AST believes that the PETAL(TM) stent system is potentially applicable to up to 25 percent of all percutaneous coronary interventions.

The BOSS study Principal Investigator, Dr. Maurice Buchbinder of Scripps Memorial Hospital in La Jolla, CA, comments that the AST PETAL(TM) stent system "is a significant advancement toward solving many of the inherent issues of bifurcation stenting" and that "the PETAL(TM) stent system likely will prove to be the optimal platform for bifurcation drug-delivery, as is now the standard of care for addressing non-bifurcation coronary lesions".

AST is a developer and manufacturer of dedicated bifurcation stent technology. For more information, please visit http://www.advancedstent.com/ .

Advanced Stent Technologies Inc.

CONTACT: Jay Brumfield, President and CEO of Advanced StentTechnologies, +1-925-930-9990



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES